In this edition, NCI director announces breast cancer diagnosis, neoadjuvant chemotherapy regimen in pancreatic cancer, gender harassment is in oncology and more.
Read the full coverage here:
NCI director announces breast cancer diagnosis, says prognosis ‘very favorable’
Neoadjuvant chemotherapy regimen extends survival in pancreatic cancer
Survey shows gender harassment is ‘strikingly common’ in oncology
Proton pump inhibitor use linked to elevated cancer risk
Memorial Sloan Kettering pauses CAR-T clinical trial to investigate patient death
References:
Katz MHG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2319.
Subbiah IM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02574.
Tran TH, et al. Abstract 1843. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva.
